Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study (CMV-IMPACT)
A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant
Sponsor: BioAnaLab
Listed as NCT01077908, this PHASE3 trial focuses on Cytomegalovirus Infection and remains completed. Sponsored by BioAnaLab, it has been updated 6 times since 2008, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2018 [monthly]
Completed PHASE3
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioAnaLab
- Cell Medica Ltd
- Commitum AB
- EMAS Pharma
- Wellcome Trust
For direct contact, visit the study record on ClinicalTrials.gov .